Brief: Onxeo To Present New Preclinical Data Highlighting Asidna’s Ability To Fight Tumor Resistance

Valerio Therapeutics SA

31/03/2022 17:51

March 31 (Reuters) - Onxeo SA  ALONX.PA :
    * ONXEO TO PRESENT NEW PRECLINICAL DATA HIGHLIGHTING
ASIDNA™’S
ABILITY TO FIGHT TUMOR RESISTANCE AND PROTECT FROM ANTICANCER
TREATMENT TOXICITY AT AACR ANNUAL MEETING 2022
    * ASIDNA™ PROVEN TO OVERCOME RESISTANCE TO TYROSINE KINASE
INHIBITORS IN LUNG CANCER MODELS
    * ASIDNA™ PROVEN TO PROTECT HEALTHY CELLS WHEN COMBINED WITH
CONVENTIONAL ANTITUMOR TREATMENTS

Source text for Eikon:  ID:nBwBtdn8a 
Further company coverage:  ALONX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))